Related Articles
PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports
High-grade serous ovarian cancer 3 years after bilateral salpingectomy: A case report
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
BRCA2 germline mutations in primary cancer of the fallopian tube
Hereditary breast and ovarian cancer susceptibility genes (Review)